Understanding the Nilotinib trials
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
New research into the cellular clearance pathways governed by the GBA gene has shown reduced activity associated with both ageing and idiopathic Parkinson’s.
A pre-clinical study has shown that low dose insulin administered through the nose can improve movement and help protect dopaminergic neurons from damage.
A new preclinical study has shown that LRRK2 inhibition in an animal model of Parkinson’s can improve lysosomal health and reduce alpha synuclein accumulation in dopaminergic neurons.
A phase II open label trial of a novel drug targeting